Sitagliptin-Metformin-Mepha retard 50/500 mg
Sitagliptin-Metformin-Mepha retard 50/500 mg is a medicine authorised by Swissmedic under authorisation number 69033. The authorisation holder is Mepha Pharma AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 18 April 2023 and the authorisation is limited until 17 April 2028. ATC code A10BD07 places the medicine in the group Drugs used in diabetes.
| Authorisation number | 69033 |
|---|---|
| Name | Sitagliptin-Metformin-Mepha retard 50/500 mg |
| Full name | Sitagliptin-Metformin-Mepha retard 50/500 mg, Tabletten mit veränderter Wirkstofffreisetzung |
| Authorisation holder | Mepha Pharma AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | A10BD07 |
| First authorisation | 18 April 2023 |
| Authorisation validity | 17 April 2028 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Sitagliptin-Metformin-Mepha retard 50/500 mg, Tabletten mit veränderter Wirkstofffreisetzung | B | 18 April 2023 |
| 2 | Sitagliptin-Metformin-Mepha retard 50/1000 mg, Tabletten mit veränderter Wirkstofffreisetzung | B | 18 April 2023 |
| 3 | Sitagliptin-Metformin-Mepha retard 100/1000 mg, Tabletten mit veränderter Wirkstofffreisetzung | B | 18 April 2023 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 60 | Tablette(n) | A10BD07 | 07.06.2. | B |
| 2 | 160 | Tablette(n) | A10BD07 | 07.06.2. | B |
| 3 | 60 | Tablette(n) | A10BD07 | 07.06.2. | B |
| 4 | 160 | Tablette(n) | A10BD07 | 07.06.2. | B |
| 5 | 30 | Tablette(n) | A10BD07 | 07.06.2. | B |
| 6 | 90 | Tablette(n) | A10BD07 | 07.06.2. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Sitagliptin-Metformin-Mepha retard 50/500 mg authorised in Switzerland?
Yes. Sitagliptin-Metformin-Mepha retard 50/500 mg is authorised by Swissmedic under authorisation number 69033, data as of 01 September 2026. The authorisation is limited until 17 April 2028.
Which dispensing category does Sitagliptin-Metformin-Mepha retard 50/500 mg have?
Sitagliptin-Metformin-Mepha retard 50/500 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Sitagliptin-Metformin-Mepha retard 50/500 mg?
The authorisation holder is Mepha Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.